Xenetic Biosciences, Inc. (NASDAQ:XBIO)

PRESS RELEASE

published on 07/30/2025 at 15:00, 1 year 1 month ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Large B Cell Lymphoma
Xenetic Biosciences collaborates with PeriNess for an exploratory clinical study of DNase I with anti-CD19 CAR T cells in large B cell lymphoma patients at Tel Aviv Sourasky Medical Center

Xenetic Biosciences DNase I PeriNess Large B Cell Lymphoma Anti-CD19 CAR T Cells
BRIEF

published on 07/23/2025 at 14:35, 1 year 2 months ago

Xenetic Biosciences étend sa collaboration avec Scripps Research

Biosciences Xénétiques Thérapie Par Cellules CAR-T Développement Préclinique Plateforme DNase-I Collaboration En Oncologie
BRIEF

published on 07/23/2025 at 14:35, 1 year 2 months ago

Xenetic Biosciences Expands Collaboration with Scripps Research

Xenetic Biosciences CAR T-cell Therapy Preclinical Development DNase-I Platform Oncology Collaboration
PRESS RELEASE

published on 07/23/2025 at 14:30, 1 year 2 months ago

Xenetic Biosciences, Inc. Expands Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform
Xenetic Biosciences expands research collaboration with TSRI to validate DNase-I data in lymphoma and leukemia models. Advancing oncology therapies with CAR T-cells

Xenetic Biosciences Research Collaboration Leukemia Lymphoma DNase-I Data
BRIEF

published on 07/08/2025 at 15:05, 1 year 2 months ago

Xenetic Biosciences met à jour sa collaboration sur l'étude de la DNase I

Étude Clinique Biosciences Xénétiques Cancer Du Pancréas ADNase I FOLFIRINOX
BRIEF

published on 07/08/2025 at 15:05, 1 year 2 months ago

Xenetic Biosciences Updates on DNase I Study Collaboration

Xenetic Biosciences Clinical Study Pancreatic Cancer DNase I FOLFIRINOX
PRESS RELEASE

published on 07/08/2025 at 15:00, 1 year 2 months ago

Xenetic Biosciences, Inc. Announces Update from Collaboration Partner of First Patient Dosed in Exploratory Clinical Study of DNase I in Combination with FOLFIRINOX for the First Line Treatment of Unresectable, Locally Advanced or Metastatic Pancreatic C
Xenetic Biosciences, Inc. announces exploratory clinical study in Israel evaluating DNase I with FOLFIRINOX for pancreatic cancer treatment

Xenetic Biosciences Pancreatic Cancer DNase I FOLFIRINOX Exploratory Clinical Study
BRIEF

published on 05/14/2025 at 14:10, 1 year 4 months ago

Xenetic Biosciences publie ses résultats financiers du premier trimestre 2025

Résultats Financiers Partenariats Stratégiques Augmentation Des Revenus Programme DNase I Collaboration Avec PeriNess
BRIEF

published on 05/14/2025 at 14:10, 1 year 4 months ago

Xenetic Biosciences Reports Q1 2025 Financial Results

Financial Results Strategic Partnerships Revenue Increase DNase I Program Collaboration With PeriNess
PRESS RELEASE

published on 05/14/2025 at 14:05, 1 year 4 months ago

Xenetic Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update
Xenetic Biosciences, Inc. focuses on strategic exploratory clinical studies with partners, progressing DNase I program, and reported $5.2 million cash for operations

Financial Results Xenetic Biosciences Immuno-oncology Clinical Studies DNase I

Published on 09/23/2026 at 22:00, 8 hours 25 minutes ago

Petrolympic Adopts Semi-Annual Financial Reporting
Published on 09/23/2026 at 18:25, 12 hours ago

Boba Mint Holdings Ltd. Reports Strong Early Subscription Adoption Following Soft Launch of Amino Pro
Published on 09/23/2026 at 15:42, 14 hours 43 minutes ago

Global Atomic Announces C$50 Million Public Offering of Units
Published on 09/23/2026 at 14:31, 15 hours 54 minutes ago

First Breach Completes First Untethered Flight of Proprietary Drone Prototype, Advancing American-Made Unmanned Systems Program
Published on 09/23/2026 at 14:30, 15 hours 55 minutes ago

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides

View all ACCESSWIRE

Published on 09/24/2026 at 05:55, 30 minutes ago

Donghai, China, Brings Crystal and Handcrafted Press-On Nails to Milan Fashion Week
Published on 09/24/2026 at 05:08, 1 hour 17 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Appendix 3G and 3H
Published on 09/24/2026 at 03:24, 3 hours ago

EQS-Adhoc: Dexus Finance Pty Limited: 2026 Notice of Annual General Meeting
Published on 09/23/2026 at 23:00, 7 hours 25 minutes ago

Correction d’un communiqué du 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNONCE LE SUCCÈS DE SON AUGMENTATION DE CAPITAL AVEC MAINTIEN DU DROIT PREFERENTIEL DE SOUSCRIPTION AINSI QU’UN REMBOURSEMENT PARTIEL D’OBLIGATIONS REMBOURSABLES EN ACTIONS
Published on 09/23/2026 at 23:00, 7 hours 25 minutes ago

Correction of a release from 23.09.2026 18:00 CET/CEST - MHM CORPORATE ANNOUNCES THE SUCCESS OF ITS CAPITAL INCREASE WITH PREFERENTIAL SUBSCRIPTION RIGHTS AND THE PARTIAL EARLY REDEMPTION OF BONDS REDEEMABLE IN SHARES

View all EQS

Published on 09/23/2026 at 19:46, 10 hours 38 minutes ago

SFPI GROUP: half year 2026 results
Published on 09/23/2026 at 19:46, 10 hours 38 minutes ago

SFPI GROUP: publication des résultats semestriels 2026
Published on 09/23/2026 at 19:14, 11 hours 11 minutes ago

Robust performance from Investments and continued execution of the strategy
Published on 09/23/2026 at 19:14, 11 hours 11 minutes ago

Performance robuste des Investissements, poursuite du déploiement de la stratégie
Published on 09/23/2026 at 18:00, 12 hours 25 minutes ago

CIS : H1 2026 results.

View all LES ECHOS COMFI WIRE

News